Britain’s National Health Service (NHS) has announced that it will not cover Eli Lilly’s new Alzheimer’s drug, donanemab.

We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...

Eli Lilly (LLY) announced “positive results” from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related ...

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...

Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a leading biopharmaceutical firm with a market cap of ...

Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

While Alzheimer’s Disease has been a tough market for drug developers, Eli Lilly has breakthrough designation from the food and drug administration (FDA) for donanemab and recently presented ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Eli Lilly (LLY) announced “positive results ... endpoint for people receiving a slightly modified titration of donanemab in adults with early symptomatic Alzheimer’s disease.

Britain’s National Health Service (NHS) has announced that it will not cover Eli Lilly’s new Alzheimer’s drug, donanemab. Initially, the NHS was expected to approve the drug this week ...